Application of new ERCC1 antibody for molecular diagnosis of platinum chemotherapy in nonsmall cell lung cancer

罗静; 徐美青; 郭明发; 魏大中; 柳常青; 孙翔翔

doi:10.3969/j.issn.1007-3969.2014.02.009

您当前的位置：

首页 >

文章列表页 >

Application of new ERCC1 antibody for molecular diagnosis of platinum chemotherapy in nonsmall cell lung cancer

更新时间：2025-12-31

- Application of new ERCC1 antibody for molecular diagnosis of platinum chemotherapy in nonsmall cell lung cancer
- China Oncology Vol. 24, Issue 2, Pages: 135-138(2014)
- 作者机构：
  
  安徽医科大学附属省立医院胸外科,安徽,合肥,230001
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2014.02.009
  CLC：
- Published Online：07 March 2014，
  
  Published：07 March 2014
- 稿件说明：
移动端阅览
罗静,徐美青,郭明发,魏大中,柳常青,孙翔翔. ERCC1新抗体在非小细胞肺癌铂类用药分子诊断中的应用[J]. 中国癌症杂志, 2014, 24(2): 135-138.

罗静, 徐美青, 郭明发, et al. Application of new ERCC1 antibody for molecular diagnosis of platinum chemotherapy in nonsmall cell lung cancer[J]. China Oncology, 2014, 24(2): 135-138.
罗静,徐美青,郭明发,魏大中,柳常青,孙翔翔. ERCC1新抗体在非小细胞肺癌铂类用药分子诊断中的应用[J]. 中国癌症杂志, 2014, 24(2): 135-138. DOI： 10.3969/j.issn.1007-3969.2014.02.009.

罗静, 徐美青, 郭明发, et al. Application of new ERCC1 antibody for molecular diagnosis of platinum chemotherapy in nonsmall cell lung cancer[J]. China Oncology, 2014, 24(2): 135-138. DOI： 10.3969/j.issn.1007-3969.2014.02.009.

摘要

背景与目的：DNA切除修复交叉互补基因1(excision repair cross complementation group l，ERCC1)的高表达与铂类药物的耐药性相关。以往研究中常采用ERCC1抗体8F1，近来发现其有非特异性。为了检测ERCC1新抗体4F9在非小细胞肺癌(non-small cell lung cancer，NSCLC)铂类用药的指导作用。方法：采用免疫组化法对72例NSCLC患者肿瘤组织进行ERCC1检测，分析患者的ERCC1蛋白表达与临床特征、铂类为基础化疗方案的疗效及患者生存期的关系。结果：72例NSCLC组织中ERCC1蛋白高表达者占55.5％。ERCC1的蛋白表达与患者的性别、年龄、组织学类型、临床分期、淋巴结转移均无明显相关性(P0.05)；ERCC1低表达患者的化疗有效率、中位生存期及2年生存率均高于高表达患者(62.5％ vs 37.5％；22.9 vs 18.4个月；46.9％vs 37.5％)，差异均有统计学意义(P0.05)。结论：ERCC1新抗体4F9免疫组化法检测ERCCl的表达有助于筛选NSCLC患者辅助化疗方案，指导患者术后铂类药物的个体化治疗。

Abstract

Background and purpose: High expression of excision repair cross-complementing 1 (ERCC1) is related to resistance in patients treated with platinum-containing regimens. The ERCC1 antibody 8F1 was usually used in past studies

but it was found to have no-specificity recently. This study aimed to investigate the predictive role of a new ERCC1 antibody 4F9 to platinum chemotherapy in non-small cell lung cancer (NSCLC) patients. Methods: Expression of ERCC1 was detected using antibody 4F9 by immunohistochemistry (IHC) in 72 NSCLC tissues. The relationship between the expression of ERCCl and the clinical pathological parameters

the efficacy of platinum chemotherapy and overall survival of patients were explored by statistical analysis. Results: The high expression of ERCCl protein was 55.5％in 72 cases. There was no significant correlation between the ERCC1 expression with gender

age

pathological type

clinical stage and lymphatic metastasis (P0.05). Patients with low expression of ERCC1 had significantly higher response rates to platinum chemotherapy

longer median survival time and 2-years survival rate comparing with those with high expression of ERCC1 (62.5％ vs 37.5％; 22.9 vs 18.4 month; 46.9％ vs 37.5％)

respectively (P0.05). Conclusion: The expression analysis of ERCC1 using new ERCC1 antibody 4F9 by IHC method is helpful to assign chemotherapeutic regimen

and guide individual platinum chemotherapy for post-operation patients.

关键词

Keywords

references

Views

1190

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy and prognostic predictors of first-generation EGFR TKI-targeted therapy in patients with EGFR-mutated advanced non-small cell lung cancer

Analysis of immune-related adverse events and its correlation with efficacy of anti-PD-1 monotherapy in advanced non-small cell lung cancer

A comparative analysis of the long-term efficacy between partial hepatectomy and transcatheter arterial chemoembolization in patients with liver metastasis from nasopharyngeal carcinoma

Research on high-throughput detection of plasma cell-free DNA for targeted therapy-related genes screening and prognosis prediction in non-small cell lung cancer patients

Clinical pathological characteristics and immune microenvironment significance of EGFR T790M mutation in non-small cell lung cancer patients and its prognostic implications

Related Author

Yaping HONG

Yunjian HUANG

Zhangzhou HUANG

Shengjia CHEN

Qiaofeng ZHONG

Hongfu ZENG

Wu ZHUANG

义维丽

Related Institution

Department of Thoracic Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital

柳州市工人医院肿瘤科

同济大学附属上海市肺科医院肿瘤科

Department of Liver Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Molecular Diagnostics, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine

AI问答

⁰